Psylo

Psylo

Private Company
Public Company
Subsidiary of
Drug Discovery

About

Psylo is Australia’s first psychedelic biotech company focused on developing psychedelic medicines to treat mental illness. The company develops psychedelics drugs to make them accessible as improved treatments to currently available selective serotonin reuptake inhibitors (SSRI) medications using psychedelic molecules, thereby enabling patients to recover from severe mental issues.

Team

Josh Ismin, CEO, is a repeat founder and biotech investor, with a BSBA and MBA from Washington University in St. Louis (where neurologist Marcus E. Rachichle coined the term “Default Mode Network”).  
Sam Banister, CSO, is a leading medicinal chemist with a proven track record in molecular discovery within academia (at University of Sydney, and Stanford) as well as with a variety of biotech startups.